The subset of genes selected for discussion in this study includes tumor-inflammation signature genes adopted from (Danaher et al., 2018), ADO-signature genes from (Fong et al., 2020), and other immune genes recognized as relevant in RCC (Supplementary Table S2; Figure 6). The gene discussed is ADO; the disease is neoplasm.